Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
Fiche publication
Date publication
janvier 2014
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Dr LIZARD Sarab, Pr PRETET Jean-Luc
Tous les auteurs :
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J
Lien Pubmed
Résumé
There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations.
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, pharmacology, Carcinoma, Non-Small-Cell Lung, drug therapy, Disease-Free Survival, Drug Resistance, Neoplasm, genetics, Exons, Female, Gene Frequency, Genetic Association Studies, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Proportional Hazards Models, Protein Kinase Inhibitors, pharmacology, Receptor, Epidermal Growth Factor, antagonists & inhibitors, Young Adult
Référence
Ann. Oncol.. 2014 Jan;25(1):126-31